Latest Conference Articles

Treatment with BVd led to favorable survival outcomes and prolonged responses vs DVd in lenalidomide-refractory patients with multiple myeloma.

The combination of daratumumab, lenalidomide, ixazomib, and dexamethasone was efficacious in transplant-ineligible, newly diagnosed myeloma.

The addition of belantamab mafodotin to standard-of-care VRd proved feasible as frontline therapy in newly diagnosed multiple myeloma.

Omar Nadeem, MD, discusses updated data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in relapsed/refractory multiple myeloma.

Paula Rodriguez-Otero, MD, discusses safety and efficacy findings with linvoseltamab, a bispecific antibody targeting BCMA, in patients with high-risk smoldering multiple myeloma.

Belantamab mafodotin plus lenalidomide and dexamethasone induced CRs or better in over half of patients with newly diagnosed multiple myeloma.

Administering the anti-GPRC5D agent MCARH109 and anti-BCMA therapy MCARH125 in tandem was feasible and tolerable in relapsed/refractory multiple myeloma.

Eque-cel was effective for the treatment of patients with relapsed/refractory multiple myeloma.

Arlo-cel given as a single infusion drove efficacy and was safe in relapsed/refractory multiple myeloma.

D-VRd led to favorable PRO outcomes in patients with newly diagnosed multiple myeloma who had MRD negativity after therapy.

Maintenance therapy with belantamab mafodotin, pomalidomide, and dexamethasone was safe and led to durable responses in high-risk myeloma.

Iberdomide plus daratumumab and dexamethasone yielded deep responses and had a manageable safety profile in transplant-ineligible multiple myeloma.

Benjamin A. Weinberg, MD, discusses the rationale for examining BXCL701 plus pembrolizumab in mPDAC.

Data from a phase 2 study suggested that fixed-duration cevostamab is both feasible and safe in patients with heavily pretreated multiple myeloma.

Jesús San Miguel, MD, PhD, discusses patient-reported outcomes and safety for patients with newly diagnosed multiple myeloma who achieved MRD negativity and a CR or better.

Linvoseltamab plus carfilzomib produced expected toxicities in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Donna Catamero, ANP-BC, OCN, CCRC, discusses the challenges community-based clinicians face in delivering bispecific antibodies and CAR T-cell therapy for multiple myeloma.

Isa-KRd led to a 74.8% MRD negativity rate in high-risk newly diagnosed multiple myeloma subgroups.

SHR-4849 showed acceptable safety and early antitumor activity in relapsed small cell lung cancer.

SHR-4849 showed acceptable safety and preliminary antitumor activity in relapsed small cell lung cancer.

Tarek Mouhieddine, MD, discusses the predictive role of ferritin levels and ALC in patients with multiple myeloma receiving bispecific antibodies.

ISB 2001 had a manageable safety profile and induced deep, durable responses at active doses in patients with relapsed/refractory multiple myeloma.

Marc S. Raab, MD, PhD, discusses the efficacy of teclistamab-based induction in patients with newly diagnosed multiple myeloma.

The combination of cevostamab, pomalidomide, and dexamethasone was deemed safe with early efficacy signals in relapsed/refractory multiple myeloma.

Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.

Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Kelsey Pan, MD, MPH, discusses notable presentations from an OncLive Fellows Forum on Thoracic Oncology.

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.